Tumor escape and progression of HER-2/neu negative breast cancer under immune pressure

Maciej Kmieciak, Kyle K. Payne, Michael O. Idowu, Margaret M. Grimes, Laura Graham, Maria Libera Ascierto, Ena Wang, Xiang Yang Wang, Harry D. Bear, Masoud H. Manjili

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: Emerging data from pre-clinical and clinical studies suggest that HER-2/neu-specific T cell responses could induce HER-2/neu antigen loss in the tumor cells. These data suggest that patients with HER-2/neu negative breast cancer might have had HER-2/neu positive premalignant lesions in the past that progressed to HER-2/neu negative breast cancer under HER-2/neu-specific immune pressure.Methods: We conducted a pilot study in patients with HER-2/neu positive and HER-2/neu negative breast cancers as well as a patient with ductal carcinoma in situ (DCIS). HER-2/neu expression was determined by FISH. HER-2/neu-specific T cell responses were determined by using IFN-γ ELISA. Expression of IFN-γ Rα in the tumors was determined by immunohistochemistry analysis of paraffin-embedded tissues.Results: We determined that majority of (10 of 12) patients with HER-2/neu negative breast cancer had HER-2/neu-specific IFN-γ producing T cell responses which was stronger than those in patients with HER-2/neu positive tumors. Such immune responses were associated with nuclear translocation of IFN-γ Rα in their tumor cells. Patient with DCIS also showed HER-2/neu-specific T cell responses.Conclusion: These data suggest that conducting retrospective studies in patients with HER-2/neu negative breast cancers and prospective studies in patients with HER-2/neu positive DCIS can determine whether HER-2/neu negative invasive carcinomas arise from HER-2/neu positive DCIS under the immune pressure.

Original languageEnglish
Article number35
JournalJournal of Translational Medicine
Volume9
DOIs
Publication statusPublished - 31 Mar 2011
Externally publishedYes

Fingerprint

Tumor Escape
T-cells
Tumors
Breast Neoplasms
Pressure
Carcinoma, Intraductal, Noninfiltrating
Cells
T-Lymphocytes
Paraffin
Neoplasms
Tissue
Antigens
Retrospective Studies
Enzyme-Linked Immunosorbent Assay
Immunohistochemistry
Prospective Studies
Carcinoma

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Kmieciak, M., Payne, K. K., Idowu, M. O., Grimes, M. M., Graham, L., Ascierto, M. L., ... Manjili, M. H. (2011). Tumor escape and progression of HER-2/neu negative breast cancer under immune pressure. Journal of Translational Medicine, 9, [35]. https://doi.org/10.1186/1479-5876-9-35

Tumor escape and progression of HER-2/neu negative breast cancer under immune pressure. / Kmieciak, Maciej; Payne, Kyle K.; Idowu, Michael O.; Grimes, Margaret M.; Graham, Laura; Ascierto, Maria Libera; Wang, Ena; Wang, Xiang Yang; Bear, Harry D.; Manjili, Masoud H.

In: Journal of Translational Medicine, Vol. 9, 35, 31.03.2011.

Research output: Contribution to journalArticle

Kmieciak, M, Payne, KK, Idowu, MO, Grimes, MM, Graham, L, Ascierto, ML, Wang, E, Wang, XY, Bear, HD & Manjili, MH 2011, 'Tumor escape and progression of HER-2/neu negative breast cancer under immune pressure', Journal of Translational Medicine, vol. 9, 35. https://doi.org/10.1186/1479-5876-9-35
Kmieciak, Maciej ; Payne, Kyle K. ; Idowu, Michael O. ; Grimes, Margaret M. ; Graham, Laura ; Ascierto, Maria Libera ; Wang, Ena ; Wang, Xiang Yang ; Bear, Harry D. ; Manjili, Masoud H. / Tumor escape and progression of HER-2/neu negative breast cancer under immune pressure. In: Journal of Translational Medicine. 2011 ; Vol. 9.
@article{dd41b2cb1d4b43fa910fca71a3a9c92f,
title = "Tumor escape and progression of HER-2/neu negative breast cancer under immune pressure",
abstract = "Background: Emerging data from pre-clinical and clinical studies suggest that HER-2/neu-specific T cell responses could induce HER-2/neu antigen loss in the tumor cells. These data suggest that patients with HER-2/neu negative breast cancer might have had HER-2/neu positive premalignant lesions in the past that progressed to HER-2/neu negative breast cancer under HER-2/neu-specific immune pressure.Methods: We conducted a pilot study in patients with HER-2/neu positive and HER-2/neu negative breast cancers as well as a patient with ductal carcinoma in situ (DCIS). HER-2/neu expression was determined by FISH. HER-2/neu-specific T cell responses were determined by using IFN-γ ELISA. Expression of IFN-γ Rα in the tumors was determined by immunohistochemistry analysis of paraffin-embedded tissues.Results: We determined that majority of (10 of 12) patients with HER-2/neu negative breast cancer had HER-2/neu-specific IFN-γ producing T cell responses which was stronger than those in patients with HER-2/neu positive tumors. Such immune responses were associated with nuclear translocation of IFN-γ Rα in their tumor cells. Patient with DCIS also showed HER-2/neu-specific T cell responses.Conclusion: These data suggest that conducting retrospective studies in patients with HER-2/neu negative breast cancers and prospective studies in patients with HER-2/neu positive DCIS can determine whether HER-2/neu negative invasive carcinomas arise from HER-2/neu positive DCIS under the immune pressure.",
author = "Maciej Kmieciak and Payne, {Kyle K.} and Idowu, {Michael O.} and Grimes, {Margaret M.} and Laura Graham and Ascierto, {Maria Libera} and Ena Wang and Wang, {Xiang Yang} and Bear, {Harry D.} and Manjili, {Masoud H.}",
year = "2011",
month = "3",
day = "31",
doi = "10.1186/1479-5876-9-35",
language = "English",
volume = "9",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Tumor escape and progression of HER-2/neu negative breast cancer under immune pressure

AU - Kmieciak, Maciej

AU - Payne, Kyle K.

AU - Idowu, Michael O.

AU - Grimes, Margaret M.

AU - Graham, Laura

AU - Ascierto, Maria Libera

AU - Wang, Ena

AU - Wang, Xiang Yang

AU - Bear, Harry D.

AU - Manjili, Masoud H.

PY - 2011/3/31

Y1 - 2011/3/31

N2 - Background: Emerging data from pre-clinical and clinical studies suggest that HER-2/neu-specific T cell responses could induce HER-2/neu antigen loss in the tumor cells. These data suggest that patients with HER-2/neu negative breast cancer might have had HER-2/neu positive premalignant lesions in the past that progressed to HER-2/neu negative breast cancer under HER-2/neu-specific immune pressure.Methods: We conducted a pilot study in patients with HER-2/neu positive and HER-2/neu negative breast cancers as well as a patient with ductal carcinoma in situ (DCIS). HER-2/neu expression was determined by FISH. HER-2/neu-specific T cell responses were determined by using IFN-γ ELISA. Expression of IFN-γ Rα in the tumors was determined by immunohistochemistry analysis of paraffin-embedded tissues.Results: We determined that majority of (10 of 12) patients with HER-2/neu negative breast cancer had HER-2/neu-specific IFN-γ producing T cell responses which was stronger than those in patients with HER-2/neu positive tumors. Such immune responses were associated with nuclear translocation of IFN-γ Rα in their tumor cells. Patient with DCIS also showed HER-2/neu-specific T cell responses.Conclusion: These data suggest that conducting retrospective studies in patients with HER-2/neu negative breast cancers and prospective studies in patients with HER-2/neu positive DCIS can determine whether HER-2/neu negative invasive carcinomas arise from HER-2/neu positive DCIS under the immune pressure.

AB - Background: Emerging data from pre-clinical and clinical studies suggest that HER-2/neu-specific T cell responses could induce HER-2/neu antigen loss in the tumor cells. These data suggest that patients with HER-2/neu negative breast cancer might have had HER-2/neu positive premalignant lesions in the past that progressed to HER-2/neu negative breast cancer under HER-2/neu-specific immune pressure.Methods: We conducted a pilot study in patients with HER-2/neu positive and HER-2/neu negative breast cancers as well as a patient with ductal carcinoma in situ (DCIS). HER-2/neu expression was determined by FISH. HER-2/neu-specific T cell responses were determined by using IFN-γ ELISA. Expression of IFN-γ Rα in the tumors was determined by immunohistochemistry analysis of paraffin-embedded tissues.Results: We determined that majority of (10 of 12) patients with HER-2/neu negative breast cancer had HER-2/neu-specific IFN-γ producing T cell responses which was stronger than those in patients with HER-2/neu positive tumors. Such immune responses were associated with nuclear translocation of IFN-γ Rα in their tumor cells. Patient with DCIS also showed HER-2/neu-specific T cell responses.Conclusion: These data suggest that conducting retrospective studies in patients with HER-2/neu negative breast cancers and prospective studies in patients with HER-2/neu positive DCIS can determine whether HER-2/neu negative invasive carcinomas arise from HER-2/neu positive DCIS under the immune pressure.

UR - http://www.scopus.com/inward/record.url?scp=79953205628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953205628&partnerID=8YFLogxK

U2 - 10.1186/1479-5876-9-35

DO - 10.1186/1479-5876-9-35

M3 - Article

C2 - 21453513

AN - SCOPUS:79953205628

VL - 9

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

M1 - 35

ER -